NCT03006237View on ClinicalTrials.gov

IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
HysterectomySurgery
Interventions
DRUG

IS-001

10mg, 20mg or 40 mg IV IS-001 drug administered during surgery

DEVICE

da Vinci® Si/Xi Surgical System

robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging

Trial Locations (1)

79902

Las Palmas Medical Center, El Paso

Sponsors

Lead Sponsor

Intuitive Surgical
All Listed Sponsors
lead

Intuitive Surgical

INDUSTRY

NCT03006237 - IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics | Biotech Hunter | Biotech Hunter